Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews

Zhongliu Fangzhi Yanjiu

HU Nanlin¹  ZHENG Fangchao¹  SI Yiran¹  YUAN Peng²  JIANG Peidi²  WANG Xue²  YUE Jian² 

[1] Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

关键词: immune checkpoint inhibitors;    immune-related adverse events;    immunotherapy;   

DOI  :  10.3971/j.issn.1000-8578.2020.19.1554

来源: DOAJ

【 摘 要 】

Objective To observe the toxicities of immune checkpoint inhibitors. Methods We retrospectively analyzed the clinical data of 20 advanced tumor patients who received immune checkpoint inhibitors therapy in Cancer Hospital of Chinese Academy of Medical Sciences from March 2017 to August 2019, and collected the immune-related adverse events. Results The median immunotherapy time was 4.0 months. The immune-related adverse events occurred in 6 patients: one case of grade Ⅰ gastroenteritis, one case of grade Ⅰ dermatitis, one case of grade Ⅰ thyroiditis, one case of grade Ⅲ hepatitis, one case of grade Ⅲ pneumonia and one case of grade Ⅳ pneumonia; the median time of occurrence was 5.3 months. Conclusion As the incidence of immune-related adverse events is relatively high and sometimes life-threatening, it is crucial for early recognition, accurate diagnosis and prompt intervention of the toxicities associated with immune checkpoint inhibitors.

【 授权许可】

Unknown